FIN-EGFRprint: a Finnish real-world study on treatments and outcomes in advanced NSCLC with common EGFR mutations
DOI:
https://doi.org/10.2340/1651-226X.2026.44731Keywords:
carcinoma, non-small-cell lung, receptor, epidermal growth factor, protein kinase inhibitors, survival rate, treatment outcome, disease progressionAbstract
Background and purpose: The treatment of advanced non-small cell lung cancer (aNSCLC) with common epidermal growth factor receptor (cEGFR) mutations has evolved substantially over the last 15 years, with the discovery of activating epidermal growth factor receptor (EGFR) mutations and introduction of first-, second- and third generation (gen) EGFR tyrosine kinase inhibitors (TKIs) as first-line therapy. This retrospective observational study aimed to evaluate whether the introduction of these treatments has led to improved ‘real-world’ outcomes over time by analysing time to next treatment (TTNT) and overall survival (OS).
Patient/material and methods: Patients (n = 379) with EGFR exon 19 deletion (Del19) or exon 21 L858R (L858R) substitution and aNSCLC were identified from two Finnish university hospital data lakes between 2010 and 2023. TTNT and OS were analysed from first-line treatment initiation using Kaplan–Meier survival and multivariable Cox regression analyses. Patients were stratified into three cohorts based on date of diagnosis and which TKIs were available at that time (1st-gen: 2010–2016, 2nd-gen: 2017–2020 and 3rd-gen: 2020–2023).
Results: The use of chemotherapy as first-line therapy declined from 32% (2010–2016) to 6% (2020–2023), while 80% of patients received 3rd-gen TKIs as first-line treatment in 2020–2023. Median TTNT improved over time (9.7 to 13.2 to 21.6), with a significant improvement in 2020–2023 versus 2010–2016 (HR: 0.46; 95% CI: 0.33–0.64; p < 0.001). Median OS also increased over time (19.1 to 23.9 to 29.3 months) and was significantly higher in 2020–2023 versus 2010–2016 (HR: 0.56; 95% CI: 0.39–0.82; p = 0.002).
Interpretation: ‘Real-world’ treatment outcomes for aNSCLC with cEGFR mutations have improved over time likely due to the transition from 1st- to 3rd-gen TKIs. However, real-word survival with TKIs remains lower than clinical trials results emphasizing the unmet need.
Downloads
References
Hsu WH, Yang JCH, Mok TS, Loong HH. Overview of current systemic management of EGFR-mutant NSCLC. Ann Oncol. 2018;29(Suppl 1):i3–9. DOI: https://doi.org/10.1093/annonc/mdx702
https://doi.org/10.1093/annonc/mdx702 DOI: https://doi.org/10.1093/annonc/mdx702
Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv192–237. DOI: https://doi.org/10.1093/annonc/mdy275
https://doi.org/10.1093/annonc/mdy275 DOI: https://doi.org/10.1093/annonc/mdy275
ESMO Living Guideline, Oncogene-Addicted Metastatic NSCLC [Internet]. Available from: https://www.esmo.org/guidelines/living-guidelines/esmo-living-guideline-oncogene-addicted-metastatic-
non-small-cell-lung-cancer/management-of-advanced-and-metastatic-disease/egfr-mutation/stage-iv-mnsclc-with-egfr-activating-mutation-before-systemic-progression
Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380–8. DOI: https://doi.org/10.1056/NEJMoa0909530
https://doi.org/10.1056/NEJMoa0909530 DOI: https://doi.org/10.1056/NEJMoa0909530
Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121–8. DOI: https://doi.org/10.1016/S1470-2045(09)70364-X
https://doi.org/10.1016/S1470-2045(09)70364-X DOI: https://doi.org/10.1016/S1470-2045(09)70364-X
Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735–42. DOI: https://doi.org/10.1016/S1470-2045(11)70184-X
https://doi.org/10.1016/S1470-2045(11)70184-X DOI: https://doi.org/10.1016/S1470-2045(11)70184-X
Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–46. DOI: https://doi.org/10.1016/S1470-2045(11)70393-X
https://doi.org/10.1016/S1470-2045(11)70393-X DOI: https://doi.org/10.1016/S1470-2045(11)70393-X
Park K, Tan EH, O’Byrne K, Zhang L, Boyer M, Mok T, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17(5):577–89. DOI: https://doi.org/10.1016/S1470-2045(16)30033-X
https://doi.org/10.1016/S1470-2045(16)30033-X DOI: https://doi.org/10.1016/S1470-2045(16)30033-X
Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376(7):629–40. DOI: https://doi.org/10.1056/NEJMoa1612674
https://doi.org/10.1056/NEJMoa1612674 DOI: https://doi.org/10.1056/NEJMoa1612674
Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41–50. DOI: https://doi.org/10.1056/NEJMoa1913662
https://doi.org/10.1056/NEJMoa1913662 DOI: https://doi.org/10.1056/NEJMoa1913662
Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113–25. DOI: https://doi.org/10.1056/NEJMoa1713137
https://doi.org/10.1056/NEJMoa1713137 DOI: https://doi.org/10.1056/NEJMoa1713137
Manninen O, Puuniemi L, Iivanainen S, Arffman M, Kaarteenaho R, Koivunen JP. Treatment outcomes of non-small cell lung cancers treated with EGFR tyrosine kinase inhibitors: a real-world cohort study. Acta Oncol. 2023;62(12):1854–61. DOI: https://doi.org/10.1080/0284186X.2023.2274481
https://doi.org/10.1080/0284186X.2023.2274481 DOI: https://doi.org/10.1080/0284186X.2023.2274481
Ekroos H, Hölsä O, Kreutzman A, Nikkola L, Vikkula J, Mattila R, et al. Metastatic NSCLC patients in the real world in Finland. Acta Oncol. 2025;64:1664–71. DOI: https://doi.org/10.2340/1651-226X.2025.44254
https://doi.org/10.2340/1651-226X.2025.44254 DOI: https://doi.org/10.2340/1651-226X.2025.44254
Nyen JE, Booth AØ, Husby Ø, Bugge C, Engebretsen I, Oteiza F, et al. Targeted treatment and survival in advanced non-squamous non-small cell lung cancer patients – a nationwide and longitudinal study. Front Oncol. 2025;15:1506041. DOI: https://doi.org/10.3389/fonc.2025.1595028
https://doi.org/10.3389/fonc.2025.1506041 DOI: https://doi.org/10.3389/fonc.2025.1506041
Gomez-Randulfe I, Scanlon LA, Carter M, Moliner L, Cil E, Califano R, et al. First-line osimertinib compared to earlier generation TKIs in advanced EGFR-mutant NSCLC: a real-world survival analysis. Lung Cancer. 2025;200:108084. DOI: https://doi.org/10.1016/j.lungcan.2025.108084
https://doi.org/10.1016/j.lungcan.2025.108084 DOI: https://doi.org/10.1016/j.lungcan.2025.108084
Lee CS, Ahmed I, Miao E, Chung S, Patel K, Kohn N, et al. A real world analysis of first line treatment of advanced EGFR mutated non-small cell lung cancer: a multi-center, retrospective study. J Oncol Pharm Pract. 2022;28(5):1140–51. DOI: https://doi.org/10.1177/10781552211020798
https://doi.org/10.1177/10781552211020798 DOI: https://doi.org/10.1177/10781552211020798
Li L, Huang Q, Sun J, Yan F, Wei W, Li Z, et al. Efficacy and safety of osimertinib for patients with EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled studies. Acta Oncol. 2022;61(11):1347–53. DOI: https://doi.org/10.1080/0284186X.2022.2132116
https://doi.org/10.1080/0284186X.2022.2132116 DOI: https://doi.org/10.1080/0284186X.2022.2132116
Gijtenbeek RGP, Damhuis RAM, van der Wekken AJ, Hendriks LEL, Groen HJM, van Geffen WH. Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in the Netherlands: a retrospective, nationwide registry study. Lancet Reg Health Eur. 2023;27:100592. DOI: https://doi.org/10.1016/j.lanepe.2023.100592
Earle CC, Venditti LN, Neumann PJ, Gelber RD, Weinstein MC, Potosky AL, et al. Who gets chemotherapy for metastatic lung cancer? Chest. 2000;117(5):1239–46. DOI: https://doi.org/10.1378/chest.117.5.1239
https://doi.org/10.1378/chest.117.5.1239 DOI: https://doi.org/10.1378/chest.117.5.1239
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2026 Aija Knuuttila, Lalli O Nurmi, Petri M Vänni, Eija K Heikkilä, Joanne Edwards, Monica H Ekblom, Irene Luccarini, Maria Silvoniemi
This work is licensed under a Creative Commons Attribution 4.0 International License.
